Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients



Status:Archived
Conditions:Hospital
Therapuetic Areas:Other
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:May 2010
End Date:June 2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Randomized and Placebo-Controlled Evaluation of Aprepitant for Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients


The study drug, Aprepitant, is currently used to control chemotherapy induced nausea and
vomiting and is also approved for post-operative nausea and vomiting. The investigators'
evaluation of it in morbidly obese patients will demonstrate its ability to control nausea
and vomiting post-operatively in this subset of patients.


The purpose of this study is to evaluate the effectiveness of Aprepitant, also known as
Emend, in reducing post-operative nausea and vomiting in morbidly obese patients.
Post-operative nausea and vomiting that occurs in morbidly obese patients can greatly
increase the chances of complications during the post-operative period. By treating
morbidly obese patients with Aprepitant, the goal is to reduce the risk of such
complications that may be induced by nausea and vomiting.


We found this trial at
1
site
Hospital of the University of Pennsylvania
3400 Spruce St
Philadelphia, Pennsylvania 19104
 (215) 662-4000
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials